Ibsrela (tenapanor) is a prescription medication approved by the FDA to treat irritable bowel syndrome with constipation (IBS-C) in adults. It works differently from older IBS-C treatments by targeting sodium absorption in the gut, which increases fluid in the intestines and helps relieve both constipation and abdominal pain.
How Ibsrela Works
Ibsrela belongs to a unique class of medication. It blocks a protein called NHE3 on the surface of intestinal cells. This protein is normally responsible for absorbing sodium (salt) from your gut into your body. When Ibsrela blocks it, more salt stays in the intestines, and water follows the salt. The result is softer, more frequent bowel movements and improved gut motility.
What makes Ibsrela distinctive is that it’s “minimally systemic,” meaning very little of the drug actually enters your bloodstream. It does most of its work locally in the intestines. This is a different approach from some other IBS-C medications that act on receptors throughout the body.
Beyond its effect on fluid, blocking NHE3 also changes the internal chemistry of intestinal cells in a way that tightens the gaps between them. This reduces how much phosphate the gut absorbs, which is why tenapanor is also used (under a different brand name) in patients on dialysis who need to lower phosphate levels. For IBS-C patients, though, the primary benefit is the increase in intestinal fluid and the relief from constipation and pain.
How Well It Works
Ibsrela was tested in two large clinical trials involving about 1,200 adults with IBS-C. To count as a “responder,” patients had to hit two targets in the same week: at least one additional complete spontaneous bowel movement per week compared to baseline, and at least a 30% reduction in their worst daily abdominal pain. They needed to achieve both in the same week for at least 6 out of 12 weeks.
In the first trial, 37% of patients on Ibsrela met that combined endpoint, compared to 24% on placebo. In the second trial, 27% on Ibsrela qualified versus 19% on placebo. Those numbers may look modest at first glance, but IBS-C is notoriously hard to treat, and placebo response rates tend to be high. Looking at the individual symptoms, about half of patients in Trial 1 (50%) saw meaningful pain relief, and 47% had improved bowel movement frequency.
Among people who responded well, many maintained that improvement over time. In a longer analysis of the first trial (26 weeks), patients on Ibsrela were significantly more likely to be consistent responders. About 18% of treated patients responded in 9 out of 12 weeks, compared to just 5% on placebo, suggesting that for the people it works for, the benefit tends to be reliable rather than sporadic.
Common Side Effects
The most frequently reported side effects (occurring in at least 2% of patients) are diarrhea, abdominal bloating, gas, and dizziness. Diarrhea is the most notable one, which makes sense given how the drug works: it’s increasing fluid in the intestines, and sometimes it overshoots the mark.
Severe diarrhea occurred in about 2.5% of patients taking Ibsrela across clinical trials, compared to 0.2% on placebo. For most people, diarrhea is mild or manageable, but if it becomes severe, stopping the medication typically resolves it. This is worth paying attention to early in treatment so you can gauge how your body responds.
Important Safety Warnings
Ibsrela carries an FDA boxed warning, the most serious type of safety alert, regarding use in children. It is contraindicated in children under 6 years old because of the risk of severe, potentially fatal dehydration. In studies on young juvenile rats, tenapanor caused deaths presumed to be from dehydration. The FDA also recommends avoiding Ibsrela in children ages 6 to 11, and the drug has not been studied or approved for anyone under 18.
If you have Ibsrela in your home, the FDA advises storing it securely and out of reach of children. Accidental ingestion by a young child could cause dangerous diarrhea and dehydration.
Ibsrela is also contraindicated in anyone with a known or suspected mechanical gastrointestinal obstruction. A physical blockage in the intestines would make increasing fluid in the gut potentially dangerous.
What to Expect as a Patient
Ibsrela is taken by mouth, typically twice daily before meals. Because clinical trials measured outcomes over 12-week periods, it’s reasonable to give the medication several weeks before judging whether it’s working for you. Some people notice improvements in bowel habits relatively quickly, but meaningful, sustained relief of both pain and constipation generally takes weeks to assess.
The drug is designed specifically for IBS-C, not for occasional constipation or other types of IBS. If your primary symptom is diarrhea rather than constipation, Ibsrela would not be appropriate. It’s also worth noting that IBS-C treatment often involves dietary changes and other strategies alongside medication, so Ibsrela is typically one piece of a broader management plan rather than a standalone fix.